We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+10.9%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.81B
AUM Growth
+$244M
Cap. Flow
-$21.2M
Cap. Flow %
-0.56%
Top 10 Hldgs %
49.66%
Holding
160
New
23
Increased
21
Reduced
32
Closed
35

Top Buys

Rank Stock Value
1
VRCA icon
Verrica Pharmaceuticals
VRCA
+$66.8M
2
MGTX icon
MeiraGTx Holdings
MGTX
+$63.1M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$56.2M
4
ISRG icon
Intuitive Surgical
ISRG
+$41.2M
5
KDMN
Kadmon Holdings, Inc.
KDMN
+$31.2M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$107M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$34.2M
4
ANAB icon
AnaptysBio
ANAB
+$24.7M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.91%
2 Industrials 0.65%
3 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTLA
151
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-440,000
Closed -$14.4M
PTLA
152
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-100,000
Closed -$158K
PGNX
153
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-162,500
Closed -$1.21M
SGYP
154
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-100,000
Closed -$183K
ABLX
155
DELISTED
Ablynx NV
ABLX
– –
-370,000
Closed -$20.2M
AVXS
156
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-276,400
Closed -$34.2M
3 4 5 6
7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Perceptive Advisors held 160 positions worth $3.81B, up 6.8% from $3.57B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors's Q2 2018 filing shows 23 new, 21 increased, 32 reduced and 35 closed positions. Its largest new stake was Verrica Pharmaceuticals: 341,041 shares worth $67.3M. The largest sale was Abiomed Inc, an estimated $107M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier, followed by Industrials and Consumer Discretionary.

  • Perceptive Advisors's largest Q2 2018 buy was Verrica Pharmaceuticals: 341,041 shares worth $67.3M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2018, an estimated $56.2M increase.
  • Perceptive Advisors's biggest Q2 2018 reduction was Abiomed Inc, cutting an estimated $107M.
  • Perceptive Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $34.2M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.81B portfolio in Q2 2018.
  • Perceptive Advisors opened 23 new positions and closed 35 in Q2 2018.
  • Perceptive Advisors's portfolio value rose 6.8% quarter-over-quarter to $3.81B.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.